¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"megakaryocyte growth and development factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • foot-and-mouth disease
    ÀԹߺ´, ±¸Á¦¿ª
  • half and half nail
    ¹Ý°ú¹Ý¼Õ¹ßÅé
  • incision and drainage
    1. Àý°³¹è³ó(¼ú) 2. Àý°³¹è¾×(¼ú)
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • kidney ureter and bladder
    ÄáÆÏ¿ä°ü¹æ±¤´Ü¼øÃÔ¿µ
  • law of weights and measures
    °è·®¹ý
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • apical growth
    ³¡¼ºÀå
  • appositional growth
    µ¡ºÙÀ̼ºÀå, ºÎ°¡¼ºÀå
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • risk factor
    À§ÇèÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • psychosocial development
    Á¤½Å»çȸ¹ß´Þ
  • sensory development
    °¨°¢¹ß´Þ
  • sexual development
    ¼º¹ß´Þ, ¼º±â´É¹ß´Þ
  • anxious and fearful personality
    ºÒ¾È°øÆ÷ÀΰÝ
  • arch and band appliance
    Ȱ¶ìÀåÄ¡
  • split pin and tube attachment
    À¯ÃʺÐÇÒÇÕÁ¤
  • babbling and lalling stage
    ¿Ë¾ËÀ̽ñâ
  • bilateral cleft lip and palate
    ¾çÂÊÀÔ¼úÀÔõÀå°¥¸²Áõ
  • bread and butter pericarditis
    »§¹öÅ͸ð¾ç½ÉÀ帷¿°
  • dilatation and curettage
    ÀڱøñÈ®Àå±Ü¾î³¿¼ú, °æ°üÈ®ÀåÀÚ±Ã¼ÒÆÄ¼ú
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
  • foot-and-mouth disease
    ÀԹ߱Áº´, ±¸Á¦¿ª
  • incision and drainage
    Àý°³¹è³ó
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • embryonal and botryoid rhabdomyosarcoma
    ¹è¾ÆÆ÷µµÈ¾¹®±ÙÀ°Á¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • DSM-I=Diagnostic and Statistical Manual of Mental Disorders-I
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 1ÆÇ
  • Death and dying
    »ç¸Á°úÀÓÁ¾
  • ENT =ear, nose and throat
    À̺ñÀÎÈİú(ÇÐ)
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • Gravity, cardiac output and
    Áß·Â(ñìÕô), ½É¹ÚÃâ·®(ãýÚÑõóÕá)
  • KUB= kidney, ureter and bladder
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • PACS (picture archiving and communicating system)
    ÆÑ½º, ¿µ»ó ÀúÀå ¹× Àü¼Û ü°è
  • PANSS=Positive and Negative Syndrome Scale
    ¾ç¼º À½¼º ÁõÈıº ôµµ
  • SADS, Schedule for Affective Disorders and Schizophrenia
    Á¤µ¿Àå¾Ö¿Í Á¤½ÅºÐ¿­º´ÀÇ Áø´ÜÀ» À§ÇÑ ¸ñ·Ï
  • SOFAS, Social and Occupational Functioning Assessment Scale
    »çȸ-Á÷¾÷±â´ÉÆò°¡Ã´µµ
  • SONAR(Sound Navigation and Ranging)
    ¼Ò³ª
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • alternate hot and cold caloric examination
    ³Ã¿Â±³´ë(¿Âµµ)Àڱذ˻ç(ÕÒè®Îßû»è®öôô§Ð½ËþÞÛ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • macrophage,macrophage derived growth factor
    ´ë½Ä¼¼Æ÷±â¿ø ¼ºÀåÀÎÀÚ(¡­ÑÃê¹ à÷íþì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡ Áõ½ÄÀÎÀÚ
  • platelet-derived growth factor(PDGF)
    Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ
  • platelet-derived growth factor(pdgf)
    ÆÇ-À¯µµ¼ºÀåÀÎÀÚ(úìá³÷ù-ë¯Óôà÷íþì×í­)
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • trasforming growth factor
    º¯È¯¼º ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü ³»ÇǼ¼Æ÷ ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    ¸Æ°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(ØæÎ·Ò®ù«á¬øàà÷íþì×í­)
  • macrophage chemotactic and activating factor
    ´ë½Ä¼¼Æ÷ ÁÖÈ­ ¹× Ȱ¼º ÀÎÀÚ
  • col factor(»ýÈ­) cÀÌ ÀÎÀÚ colicin factor
    Äݸ®½ÅÀÎÀÚ.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • arrested development
    ¹ß´ÞÁ¤Áö.
  • atypical development
    ºñÁ¤Çü ¹ß´Þ
  • bone development =b. formation
    °ñ¹ß»ý(ÍéÛ¡ßæ).
  • child development
    ¼Ò¾Æ¹ß´Þ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • density-dependent growth
    "¹ÐµµÀÇÁ¸ ¼ºÀå(ÚËÓøëîðíà÷íþ), (ÔÒ) contact inhibition"
  • exponential growth
    Áö¼ö ¼ºÀå (ò¦â¦à÷íþ)
  • exponential growth rate constant
    Áö¼ö ¼ºÀå¼Óµµ »ó¼ö (ò¦â¦à÷íþáÜÓøßÈâ¦)
  • fibroblast growth factors
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀÚÀÎÀÚ (àéë«ä´á¬øàà÷íþì×í­)
  • growth curve
    ¼ºÀå°î¼± (à÷íþÍØàÊ)
  • growth hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó
  • growth hormone regulatory hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó Á¶Àý(ðàï½) È£¸£¸ó
  • growth hormone release-inhibiting hormone
    ¼ºÀå(à÷íþ) È£¸£¸ó ¹æÃâÀúÇØ (Û¯õóîÁúª) È£¸£¸ó
  • growth hormone releasing hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó ¹æÃâ (Û¯õó)È£¸£¸ó
  • growth medium
    ¼ºÀå¹èÁö (à÷íþÛÆò¢)
  • growth rate constant
    ¼ºÀå¼Óµµ »ó¼ö (à÷íþáÜÓøßÈâ¦)
  • growth retardant
    ¼ºÀåÁö¿¬Á¦(à÷íþòÀæÅð¥)
  • head growth
    ¸Ó¸®¼ºÀå (à÷íþ)
  • headward growth
    ¸Ó¸®ÂÊ ¼ºÀå(à÷íþ)
  • linear growth
    ¼±Çü¼ºÀå(àÊû¡à÷íþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
G and D growth and development
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CFU-Meg Colony-forming units-megakaryocyte
MK Megakaryocyte
Meg Megakaryocyte
BFU-MK burst forming unit megakaryocyte
CFU-GEMM colony forming unit-granulocyte, erythroid, macrophage, megakaryocyte
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • exclusively centrifugal growth
    ¹èŸÀû ¿ø½É ¼ºÀå
  • exponential growth
    Áö¼ö Áõ½Ä
  • exponential phase of growth
    ´ë¼ö Áõ½Ä±â, °¡¼Ó ¼ºÀå±â
  • horizontal growth
    ¼öÆò ¼ºÀå
  • human growth hormone
    ¼ºÀå È£¸£¸ó
    ¼ºÀåÀ» ÃËÁøÇÏ´Â ¹°ÁúÀ» ÃÑĪÇϸç, ƯÈ÷ ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÀ» ¸»ÇÑ´Ù.
  • neural growth
    ½Å°æ°èÇü ¼ºÀå
  • no growth
    ¹«¼ºÀå
  • nonbleeding growth
    ºñÃâÇ÷¼º ¼ºÀå
  • one step growth
    ÀÏ´Ü Áõ½Ä
  • papillomatous growth
    À¯µÎ¼º ¼ºÀå
    À¯µÎÁ¾°ú °°ÀÌ ´Ù¹ßÀûÀ¸·Î ÀϾ´Â ¼ºÀå.
  • polypoid growth
    Æú¸³ Áõ½Ä
  • prenatal facial growth
    Ãâ»ýÀüÀÇ ¾ó±¼ ¼ºÀå
  • proliferative growth
    Áõ½Ä¼º ¼ºÀå
  • retardation of growth
    ¼ºÀå Áö¿¬
  • somatic growth
    ½ÅüÇü ¼ºÀå, ü¼º ¼ºÀå
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
insulin-like growth-factor-binding-protein 5 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like-growth-factor-binding protein 6 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding proteins A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9)
(12 Dec 1998)
insulin-like growth factor I <chemical> A well-characterised basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to insulin-like growth factor II, which is a major foetal growth factor.
Chemical name: Insulin-like growth factor I
(12 Dec 1998)
insulin-like growth factor II <chemical> A well-characterised neutral peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be a major foetal growth factor in contrast to insulin-like growth factor I, which is a major growth factor in adults.
Chemical name: Insulin-like growth factor II
(12 Dec 1998)
T-cell growth factor <cytokine> A hormone-like substance released by stimulated T lymphocytes, causes activation and differentiation of other T lymphocytes independently of antigen.
A type of interleukin, a chemical messenger, a substance that can improve the body's response to disease. It stimulates the growth of certain disease-fighting blood cells in the immune system.
It is secreted by Thl CD4 cells to stimulate CD8 cytotoxic T-1yrnphocytes. Interleukin 2 also increases the proliferation and maturation of the CD4 cells themselves. During HIV infection, Interleukin-2 production gradually declines.
Use of interleukin 2 therapy is under study as a way to raise CD4 cell counts and restore immune function.
Acronym: IL-2
(12 Dec 1998)
T-cell growth factor-1 <cytokine> A hormone-like substance released by stimulated T lymphocytes, causes activation and differentiation of other T lymphocytes independently of antigen.
A type of interleukin, a chemical messenger, a substance that can improve the body's response to disease. It stimulates the growth of certain disease-fighting blood cells in the immune system.
It is secreted by Thl CD4 cells to stimulate CD8 cytotoxic T-1yrnphocytes. Interleukin 2 also increases the proliferation and maturation of the CD4 cells themselves. During HIV infection, Interleukin-2 production gradually declines.
Use of interleukin 2 therapy is under study as a way to raise CD4 cell counts and restore immune function.
Acronym: IL-2
(12 Dec 1998)
T-cell growth factor-2 <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells.
Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages.
Acronym: IL-4
(12 Dec 1998)
transforming growth factor <growth factor> Proteins secreted by transformed cells that can stimulate growth of normal cells.
Unfortunate misnomer, since they induce aspects of transformed phenotype, such as growth in semi solid agar, but do not actually transform.
Transforming growth factor alpha, 50 amino acid polypeptide originally isolated from viral transformed rodent cells, contains EGF like domain and binds to EGF receptor. Stimulates growth of microvascular endothelial cells, i.e. Is angiogenic.
Transforming growth factor beta a homodimer of two 112 chains, polypeptide is secreted by many different cell types, stimulates wound healing but in vitro is also a growth inhibitor for certain cell types. The transforming growth factor family includes many of the bone morphogenetic proteins.
Acronym: TGF
(18 Nov 1997)
transforming growth factor alpha Factor isolated in a variety of tissues including epithelium, and maternal decidua. It is closely related to epidermal growth factor (epidermal growth factor-urogasterone) and binds to the egf receptor. Tgf-alpha acts synergistically with tgf-beta in inducing phenotypic transformation, but its physiological role is unknown.
(12 Dec 1998)
transforming growth factor beta Factor synthesised in a wide variety of tissues including platelets, placenta, and both normal and transformed cell lines. It acts synergistically with tgf-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. Tgf-beta also has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. There are at least three forms of tgf-beta: tgf-beta1, tgf-beta2, and tgf-beta1.2. The latter is a heterodimer made up of both tgf-beta1 and tgf-beta2.
(12 Dec 1998)
endothelium-derived growth factor synthase <enzyme> Converts l-arginine to a smooth muscle relaxing factor and stimulates the formation of cyclic-GMP
Registry number: EC 1.5.1.-
Synonym: edrf synthase
(26 Jun 1999)
epidermal growth factor <growth factor> A mitogenic polypeptide initially isolated from male mouse submaxillary gland.
The name refers to the early bioassay, but epidermal growth factor is active on a variety of cell types, especially but not exclusively epithelial. Human equivalent originally named urogastrone owing to its hormone activity.
Acronym: EGF
(18 Nov 1997)
epidermal growth factor receptor protein-tyrosine kinase <enzyme> The catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of epidermal growth factor receptor.
Registry number: EC 2.7.1.-
(12 Dec 1998)
epidermal growth factor-urogastrone <chemical> Single chain, nonhelical, acidic polypeptides of about 52 amino acids found in most mammals. Epidermal growth factor and urogastrone are not identical but seem to share biological acivities. They promote growth of, and cell proliferation in, certain tissues, especially epidermal structures and inhibit acid secretion by the stomach. They have been used to treat gastrointestinal ulcers.
Chemical name: Epidermal growth factor
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Rh factor
    ¸®¼­½º ÀÎÀÚ(ÀûÇ÷±¸ ¼Ó¿¡ ÀÖ´Â ÀÀÇ÷¼Ò)
  • Rhesus factor(antigen)
    =RH FACTOR
  • coal-factor
    ¼®Åº Áß°³ »óÀÎ(µµ¸Å »óÀÎ)
  • common factor
    =COMMON DIVISOR
  • conversion factor
    (¹®ÀÇ.ÀÚ·áû±¸¿¡¼­ ½ÇÁ¦ »óǰ±¸¸ÅÀÎÀ¸·ÎÀÇ)ÀüȯÀ²
  • factor
    ¿ä¼Ò;¿äÀÎ;¿øÀÎ;Àμö;ÀÎÀÚ;°è¼ö;À²;´ë¸®»ó;µµ¸Å»ó;Á߸ÅÀÎ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
  • again and again
    ¹Ýº¹Çؼ­
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á